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Update on the Biocompatibility of Hemodialysis Membranes
Nicholas A. Hoenich
The blood of patients treated by dialysis is repeatedly exposed to foreign materials contained in the extra-
corporeal circuit, within which the membrane contained in the dialyzer is the largest element. Traditionally,
the membrane was considered simply as a barrier between the blood and the dialysis fluid. However, the
contact is also associated with the activation of coagulation, immune and cellular pathways, and the importance
of repeated contact (often broadly referred to as “biocompatibility”) has become an important clinical issue.
Links between renal failure, dialysis and inflammation, and the role played by dialysis fluid has further
focused on the membrane. The purpose of this paper is to review the recent developments in hemodialysis
membranes, and to discuss their biocompatibility and role played in morbidity and mortality associated with
dialysis treatment. [Hong Kong J Nephrol 2004;6(2):74–8]
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INTRODUCTION
The process of hemodialysis is essentially a procedure
whereby molecular solutes, accumulated as a con-
sequence of metabolism and dietary product break-
down, and fluid are removed from the blood across a
semipermeable membrane contained in the artificial
kidney or hemodialyzer. The hemodialyzer forms a
part of the extracorporeal circuit and represents the
major non-physiologic surface to which the blood is
exposed.
Historically, membranes were considered passive
permselective barriers. However, since the patient’s
blood is repeatedly exposed to such materials, the im-
portance of such contact (often broadly referred to as
“biocompatibility”) has become an important clinical
issue. The recognition of links between renal failure,
dialysis and inflammation, and the role played by
dialysis fluid has further focused on the membrane as
a barrier to endotoxins and endotoxin fragments.
The purpose of this paper is to review the recent de-
velopments in hemodialysis membranes and discuss
their biocompatibility and the role played in morbidity
and mortality associated with dialysis treatment.
MATERIALS AND STRUCTURE OF DIALYSIS
MEMBRANES
Although membranes may be manufactured from a
variety of materials, those used historically for blood
purification owe their origins to cellulose tubing used
in food manufacture. Cellulose-based membranes re-
mained the sole category of membrane until the 1970s,
when the first synthetic membranes were introduced.
The classical cellulose membranes were supplemented
by modified cellulose membranes in the 1980s; today,
a wide range of cellulosic and synthetic materials are
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available for use in renal replacement therapy. Industrial
estimates indicate that in 1984, the worldwide use of
unmodified cellulose, modified cellulose, and synthetic
membranes was 75%, 15%, and 10%, respectively,
which had changed to 10%, 39%, and 51% by 2001.
The clinician is faced with a bewildering choice
of membranes (Table). Comparative classification of
membranes is complex. Different comparison criteria
such as membrane permeability, structure, and bioreac-
tivity have all been used, but there is no internationally
agreed classification. The classification in the Table
compares membranes in terms of their chemical com-
position. The list is not exhaustive as new membranes
are continuously being introduced.
The selection of a membrane is made on a number
of different criteria, the most important being solute
transport and hydraulic permeability characteristics and
the treatment philosophy. For example, low-flux dialy-
sis favoring the removal of low-molecular-weight sol-
utes may be performed using membranes manufac-
tured from cellulose, modified cellulose, or synthetic
polymer blends. High-flux dialysis offering enhanced
removal of small molecules and reduced treatment times
(when used in combination with high blood and dialy-
sate flow rates) can be performed with modified cellu-
lose or synthetic membranes. Such treatment, how-
ever, remains inferior in its ability to remove larger
molecular-weight solutes compared to hemodiafiltra-
tion or hemofiltration, which require the use of high-
flux membranes. Such membranes are predominantly
manufactured from synthetic materials. Other factors
determined by local economic or environmental consid-
erations can also play a role in the ultimate choice.
BIOCOMPATIBILITY OF HEMODIALYSIS
MEMBRANES
The definition of biocompatibility in the Dictionary of
Biomaterials is “the ability of a material to perform
with an appropriate response in a specific application”.
This definition is based on the principle that a bio-
material has to perform and not simply exist, that it
has to be associated with appropriate responses to en-
sure satisfactory performance. It recognizes that the
response to a material will vary from one situation to
another, and that the appropriateness may vary. Fur-
thermore, it allows a distinction to be made between
biocompatibility and biologic safety. The main diffi-
culty with this definition is that the applications of
materials in the clinical setting are varied and there may
be little commonality with the appropriateness of the
responses. Williams, responsible for the original defini-
tion, has recently suggested that the biocompatibility
of a medical device that is repeatedly in contact with
blood may be considered as “the ability of the device
to carry out its intended function within flowing blood,
with minimal interaction between device and blood
that adversely affects device performance, and without
inducing uncontrolled activation of cellular or plasma
protein cascades” [1]. Based on this definition, mem-
branes with minimal activation of cellular or plasma
protein cascades may be considered biocompatible.
BIOLOGIC EVENTS AT THE MEMBRANE SURFACE
The membrane in a dialyzer represents a large non-
Table. Hemodialysis membranes
Classical cellulose Manufactured by a regeneration process Cellulose
Cuprophanº
Modified cellulose Membranes in which the hydroxyl groups forming part of the cellulose molecule HemophanTM
are substituted or modified during the manufacturing process ExcerbaneTM
SMCTM
Cellulose acetate
Cellulose tri-acetate
Cellulose di-acetate
PEG modified cellulose
Synthetic Naturally hydrophilic Ethylene vinyl alcohol
Hydrophilic through blending or manufacturing process Polysulfone*
Polyethersulfone*
Polyamide
Polyacrylonitrile*
Polymethylmethacrylate
Polyarylethersulfone*
PolyamixTM
*Available from a range of manufacturers.
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is difficult to eradicate. Such films are dynamic and
release bacteria and endotoxins with cytokine-inducing
activity [10]. The membrane may act as a barrier to the
transport of intact bacteria into the circulation, but
lipopolysaccharide (LPS) fragments have the capac-
ity to pass across the membrane. Both cellulose and
synthetic membranes can adsorb LPS fragments,
although the adsorption is minimal in the case of
cellulose. Adsorption in synthetic membranes occurs
in the outer layer of the membrane and is governed by
the hydrophobicity of the membrane, the polymer
composition, and the asymmetric structure of the
membrane (Figure 2). It should be emphasized,
however, that not all synthetic membranes have the
same ability to retain endotoxins [11]. The potential of
synthetic membranes to adsorb cytokine-inducing
fragments has led to their use as dialysis fluid filters,
adding extra protection for the patient (Figure 3).
Utilization of such filters to improve the quality of
dialysis fluid has resulted in improvement in patient
nutritional status, inflammation, and response to
erythropoietin [12–15].
DOES BIOCOMPATIBILITY INFLUENCE PATIENT
MORTALITY AND MORBIDITY?
Links between the development of clinical problems
and the membrane type have been suggested in retro-
spective analyses [16]. Cardiac events are a major cause
of death in dialyzed patients. This is due, at least in
part, to the high prevalence of atherosclerotic coronary
heart disease. To a large extent, coronary lesions are
acquired in the predialytic phase of chronic renal failure,
but factors related to the dialysis procedure itself may
also influence early or late events in atherogenesis. The
second most common cause of death in dialysis patients
is infection. Activated proinflammatory pathways have
the potential to produce a diminished immune response.
physiologic surface to which blood is exposed during
each treatment. Such exposure results in the deposition
of proteins onto the membrane surface, activation of
the complement system, kinin, and coagulation and
fibrinolytic pathways, as well as activation of the
cellular elements of blood on each occasion (Figure
1). The magnitude of these events is governed by a
variety of factors, including chemical composition and
surface character, with synthetic materials outperfor-
ming materials based on cellulose in many indices
[2,3]. The distinction between modified cellulose
and synthetic materials, however, is less distinct. Both
cellulose-based and synthetic membranes tend to be
treated as generic groups. However, despite a similarity
in the base material, membranes can behave in different
ways when in contact with blood [4]. This is due partly
to the material surface and partly to other factors related
to the patient (anticoagulation, hemodynamic stability)
or the treatment technique.
A clear understanding of the reasons for differences
between membranes manufactured from similar blends
of materials, e.g. polysulfone, is lacking. Recent studies
suggest that the differences may be a result of variation
in the degree of cross linkage between the polymers
used [5].
The characterization of membranes in terms of
biocompatibility can be made on the basis of a num-
ber of different parameters. Historically, complement
activation (and the associated neutropenia due to the
activation of complement receptors on the cells) was
widely used for comparing membranes. Since many of
the events associated with membrane blood contact
have clinical sequelae, current emphasis focuses on
the elucidation of the molecular mechanisms involved,
for example, the release of oxygen radicals (oxidative
stress) and intra-granular proteases secondary to
neutrophil activation. This is of clinical interest since
oxidative stress contributes to morbidity in hemo-
dialysis patients, but the role of the membrane remains
unclear [6,7]. Clearly, it would be of benefit to minimize
generation of oxidative stress by the membrane. One
approach has been to bond vitamin E to the membrane
[8].
Membranes are permeable, and while the extra-
corporeal circuit is sterile, this is not the case for the
dialysis fluid pathway. Patients undergoing regular
dialysis treatment are subject to inflammation [9].
Although inflammation can arise from a variety of
causes, the water used to prepare the dialysis fluid
undergoes rigorous treatment to remove chemical
contaminants. The absence of chlorine in the treated
water permits the proliferation of bacteria in the distri-
bution network unless there is rigorous attention to the
sterilization and design of the water distribution net-
work and dialysate pathways. Bacterial proliferation
leads to the formation of biofilm which, once formed,
Figure 1. Blood pathway activation following material contact.
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Definitive evidence relating to the role of biocompati-
bility and outcomes is lacking, as the results of prospec-
tive randomized studies are conflicting. Furthermore,
it has been difficult practically to separate the effects
of biocompatibility and flux [17,18].
The recently completed HEMO study sought to
address this complex issue [19]. However, the results
indicated that death from any cause was not signifi-
cantly influenced by either the dose of dialysis or the
flux of the dialysis membranes used. The use of high-
flux dialysis, however, was associated with reduced
risks of specific cardiac-related events. The effect of
high-flux dialysis on all-cause mortality seemed to
vary, depending on the duration of prior dialysis, since
patients entered the study after varying periods on
dialysis. A European study (the Membrane Permeabil-
ity Outcomes study) addresses this issue in that only
patients new to dialysis have been included. The results
from this study are expected in 2005.
The HEMO study also found that, in respect of
infection, the likelihood of infection-related death did
not differ between patients treated with high-flux or
low-flux membranes.
It has been speculated that membrane biocompati-
bility may have a role in patient survival and recovery
of renal function in acute renal failure. However, a
recent meta-analysis by Subramanian et al showed that
synthetic membranes appeared to confer a significant
survival advantage over cellulose-based membranes
(cumulative odds ratio, OR, for survival, 1.37; 95%
confidence interval, CI, 1.02–1.83; p = 0.03) [20]. There
was, however, no association between membrane type
and recovery of renal function (cumulative OR, 1.23;
95% CI, 0.90–1.68; p = 0.18). As with chronic renal
failure, outcomes are likely to be dictated by factors
other than the membrane, such as comorbid conditions
and the dose of dialysis [21].
FUTURE DEVELOPMENTS
Membranes have evolved into barriers with well-
defined functionality and minimal bioreactivity. The
adequacy of treatments is still largely assessed by the
ability to remove low-molecular-weight non-protein-
Figure 2. (A) Membrane structure of polymer blended membranes.
Three distinct regions are visible: an inner selective layer with an
approximate thickness of 0.1–0.5 mm, a support layer to stabilize
the inner layer, and a finger-type support structure that gives the
membrane additional mechanical stability. This layer has a thickness
of 40–45 mm and presents an external skin with hydrophobic
domains. These hydrophobic domains are critical in endotoxin en-
trapment from the dialysis fluid. (B) Visualization of endotoxin
trapping in the wall of a synthetic membrane manufactured from a
polyester-polymer alloy. The highest density is seen on the outer
wall of the fiber, with no detectable endotoxin in the blood lumen.
(Adapted from: Hayama M, et al. Visualization of distribution of
endotoxin trapped in an endotoxin-blocking filtration membrane.
J Membr Sci 2002;210:45–53. Reproduced with permission.)
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Figure 3. The Hospal Diaclear filter forming part of the dialysate
fluid pathway used in the maintenance of a high level of microbio-
logic purity in dialysis fluid.
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bound solutes such as urea. Despite this, removal
of some low-molecular-weight compounds such as
phosphate remains inadequate [22]. Evidence is al-
so accumulating that the inability to remove low-
molecular-weight proteins and peptides results not
only in complications arising from their elevated lev-
els, but also from their chemical modification by
advanced glycation endproducts (AGEs) or advanced
lipoxidation endproducts, for example, the develop-
ment of dialysis-related amyloidosis [23]. AGEs al-
so play a role in the development of endothelial dys-
function and the development of atherosclerosis [24].
Adequate removal may require the use of alternate
non-membrane-based approaches such as adsorptive
techniques or the inhibition of AGE formation [25].
CONCLUSIONS
A wide range of membranes are available for use in the
treatment of renal failure. The universal use of one brand
of membrane in favor of another is impractical. The
question of whether synthetic membranes should be
used in preference to cellulose or modified cellulose
membranes based on available evidence favors synthe-
tic membranes, but such use may be at an additional
cost, particularly if high-flux synthetic membranes are
to be used [17].
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